[1]郝珊瑚,纪立秋,王治国,等.黄芪注射液联合131I核素治疗分化型甲状腺癌临床研究[J].西部中医药,2020,33(03):97-100.[doi:10.12174/j.issn.1004-6852.2020.03.27]
 HAO Shanhu,JI Liqiu,WANG Zhiguo,et al.Clinical Study on Huangqi Injection Combined with 131I Nuclide in the Treatment of Differentiated Thyroid Cancer[J].Western Journal of Traditional Chinese Medicine,2020,33(03):97-100.[doi:10.12174/j.issn.1004-6852.2020.03.27]
点击复制

黄芪注射液联合131I核素治疗分化型甲状腺癌临床研究
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年03期
页码:
97-100
栏目:
报道·衷中参西
出版日期:
2020-03-15

文章信息/Info

Title:
Clinical Study on Huangqi Injection Combined with 131I Nuclide in the Treatment of Differentiated Thyroid Cancer
文章编号:
1004-6852(2020)03-0097-04
作者:
郝珊瑚纪立秋王治国张彤张文文葛香妍李根张国旭
中国人民解放军北部战区总医院核医学科,辽宁 沈阳 110016
Author(s):
HAO Shanhu JI Liqiu WANG Zhiguo ZHANG Tong ZHANG Wenwen GE Xiangyan LI Gen ZHANG Guoxu△
Department of Nuclear Medicine, General Hospital of PLA Northern Theater Command, Shenyang 110016, China
关键词:
甲状腺癌分化型黄芪注射液131I核素生存质量临床研究
Keywords:
thyroid cancer differentiated Huangqi injection 131I nuclide survival quality clinical study
分类号:
R736.1
DOI:
10.12174/j.issn.1004-6852.2020.03.27
摘要:
目的:观察黄芪注射液联合131I核素治疗分化型甲状腺癌(differentiated thyroid cancer,DTC)的临床疗效。方法:将TC患者120例按照住院顺序随机分为对照组和治疗组各60例,对照组给予131I核素每次250 mCi,共3~5次,每次间隔4个月,观察组在对照组基础上加用黄芪注射液40 mL+5%葡萄糖溶液500 mL静脉滴注。比较治疗前后两组患者血常规[红细胞(red blood cell,RBC)、白细胞(white blood cell,WBC)、血小板(platele,PLC)、淋巴细胞(lymphocyte,LC)]、肝肾功能[谷丙转氨酶(glutamic-pyruvic transaminase,ALT)、谷草转氨酶(glutamic-oxalacetic transaminease,AST)、碱性磷酸酶(alkaline phosphatase,ALP)、肌酐(serum creatinine,SCr)、尿素氮(blood urea nitrogen,BUN)]、15 min摄锝率(UR15)、唾液的最大排泄量(MS)及卡氏功能状态评分。结果:1)两组患者治疗前后RBC、ALT、AST、ALP、SCr及BUN等指标比较差异均无统计学意义(P>0.05);治疗后WBC、PLT及LC较治疗前降低,差异有统计学意义(P<0.05),且治疗组治疗后WBC、PLT及LC低于对照组,差异有统计学意义(P<0.05)。2)两组治疗前后双侧腮腺UR15和MS比较差异有统计学意义(P<0.05),治疗后双侧颌下腺UR15和MS治疗前比较略有改变,但差异无统计学意义(P>0.05),且治疗组双侧腮腺UR15和MS低于对照组,差异有统计学意义(P<0.05)。3)治疗组近期生存质量(卡氏功能状态评分)与对照组比较升高,差异具有统计学意义(P<0.05);4)对照组总有效率为76.7%(46/60),低于治疗组的90.00%(54/60),两组比较差异有统计学意义(P<0.05)。结论:黄芪注射液联合131I核素可有效治疗分化型甲状腺癌,能提高DTC患者的近期疗效及生存质量,并能减轻131I核素化疗后引起的不适症状。
Abstract:
Objective: To observe clinical effects of Huangqi injection combined with 131I nuclide in the treatment of differentiated thyroid cancer(DTC). Methods: All 120 TC patients were randomized into the control group and the treatment group according to hospitalization sequence, 60 cases each group, the control group were given 131I nuclide, 250 mCi each time, for three to five times, the interval was four months, the observation group accepted intravenous dripping of Huangqi injection, 40 mL, and 5% glucose solution, 500 mL, based on the therapy the control group accepted. To compare blood routine test(RBC, WBC, PLT and LC), liver function(ALT, AST, ALP, SCr and BUN), 15-minute technetium uptake rate(UR15), maximum secretion(MS) and karnofsky performance status (KPS) score in both groups before and after treating. Results: 1) The difference had no statistical meaning in RBC, ALT, AST, ALP, SCr, BUN and others before and after treating in both groups (P>0.05); WBC, PLT and LC after treating reduced compared with before treating, and the difference had statistical meaning (P<0.05), and the treatment group was superior to the control group in WBC, PLT and LC after treating, and the difference showed statistical meaning(P<0.05). 2)The difference showed statistical meaning in UR15 and MS in bilateral parotid glands before and after treating between both groups(P<0.05), after treating, UR15 and MS in bilateral submandibular glands changed slightly compared with before treating, while the difference had no statistical meaning(P>0.05), and the treatment group was superior to the control group in UR15 and MS in bilateral parotid glands, and the difference showed statistical meaning(P<0.05). 3)Short-term survival quality(KPS scores) of the treatment group rose compared with the control group, and the difference presented statistical meaning(P<0.05); 4) Total effective rate of the control group was 76.7%(46/60), lower than 90.0%(54/60) of the treatment group, and the difference had statistical meaning(P<0.05). Conclusion: Huangqi injection combined with 131I nuclide could effectively treat DTC, it could raise short-term effects of DTC patients and survival quality, relieve the discomforts induced by 131I nuclide chemotherapy.

备注/Memo

备注/Memo:
收稿日期:2019-03-20作者简介:郝珊瑚(1976—),女,硕士学位,主治医师。研究方向:核素治疗。△通讯作者:张国旭(1973—),男,硕士学位,主任医师。研究方向:分子影像诊断学核素治疗。
更新日期/Last Update: 2020-03-15